Merck’s New Therapeutic For Clostridium Difficile Infection
Antara Dutta Choudhury | | Sep 21, 2015 08:55 AM EDT |
A study conducted by the international pharmaceutical company Merck discovered an experimental antibody that claims to reduce the recurrence of Clostridium difficile infection by 10 percent.
A study conducted by the international pharmaceutical company Merck discovered an experimental antibody that claims to reduce the recurrence of Clostridium difficile infection by 10 percent.
Merck will submit drug application to seek regulatory approval for new therapeutic for C. difficile infection, bezlotoxumab, in the United States, the European Union and Canada this year. Two Phase 3 clinical trials for Merck's monoclonal antibody, bezlotoxumab, licensed from UMass Medical School's MassBiologics met their primary efficacy endpoint of the reduction in C. difficile recurrence through week 12 versus placebo.
Like Us on Facebook
Bezlotoxumab is designed to block the ability of a toxin to bind to cells and thus reduces the risk of C. difficile infection recurrence by 15 percent. The studies found out that the infection recurred in about 25 percent of patients treated with antibiotics and a placebo.
The results of the study were presented at the Interscience Conference of Antimicrobial Agents and Chemotherapy and International Congress of Chemotherapy and Infection (ICC) joint meeting in San Diego on Sunday, Sept. 20.
According to Reuters, Nick Kartsonis, associate vice president in clinical research, infectious diseases at Merck said, "We have therapies to treat the initial episode, but this infection comes back frequently - there is a 25 percent risk of recurrence after the first time, and that rises to 40 percent or even 60 percent after the second infection."
According to the U.S. Centers for Disease Control and Prevention, C. difficile affects the digestive system and causes more serious intestinal conditions such as colitis. The incidence of C. difficile infection has risen sharply over the last two decades and is now a leading cause of healthcare-acquired infections in community hospitals in the U.S.
Dr. Eliav Barr, vice president infectious diseases at Merck Research Laboratories said, "Today, with increasing concerns about the rise of antimicrobial resistance, we continue to advocate for appropriate and responsible use of these important medicines," reports Latinos Health.
TagsMerck's Monoclonal Antibody, Clostridium difficile infection, Colitis, diarrhea, Clostridum Difficile Infection Recurrence
©2015 Chinatopix All rights reserved. Do not reproduce without permission
EDITOR'S PICKS
-
Did the Trump administration just announce plans for a trade war with ‘hostile’ China and Russia?
-
US Senate passes Taiwan travel bill slammed by China
-
As Yan Sihong’s family grieves, here are other Chinese students who went missing abroad. Some have never been found
-
Beijing blasts Western critics who ‘smear China’ with the term sharp power
-
China Envoy Seeks to Defuse Tensions With U.S. as a Trade War Brews
-
Singapore's Deputy PM Provides Bitcoin Vote of Confidence Amid China's Blanket Bans
-
China warns investors over risks in overseas virtual currency trading
-
Chinese government most trustworthy: survey
-
Kashima Antlers On Course For Back-To-Back Titles
MOST POPULAR
LATEST NEWS
Zhou Yongkang: China's Former Security Chief Sentenced to Life in Prison
China's former Chief of the Ministry of Public Security, Zhou Yongkang, has been given a life sentence after he was found guilty of abusing his office, bribery and deliberately ... Full Article
TRENDING STORY
-
China Pork Prices Expected to Stabilize As The Supplies Recover
-
Elephone P9000 Smartphone is now on Sale on Amazon India
-
There's a Big Chance Cliffhangers Won't Still Be Resolved When Grey's Anatomy Season 13 Returns
-
Supreme Court Ruled on Samsung vs Apple Dispute for Patent Infringement
-
Microsoft Surface Pro 5 Rumors and Release Date: What is the Latest?